Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

Cazzaniga M. E.; Cortesi L.; Ferzi A.; Scaltriti L.; Cicchiello F.; Ciccarese M.; Della Torre S.; Villa F.; Giordano M.; Verusio C.; Nicolini M.; Gambaro A. R.; Zanlorenzi L.; Biraghi E.; Legramandi L.; Rulli E.

首页> 外文期刊>Breast cancer research and treatment. >Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

【24h】

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

机译：在晚期HER2阴性乳腺癌患者中，口服长春瑞滨（mVNR）和卡培他滨（mCAPE）进行节律化疗：这是优化疾病控制的一种方法吗？ VICTOR-2研究的最终结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm these results.

机译：VICTOR-1研究表明，长春瑞滨和卡培他滨的全口服节律组合在激素受体阳性/ HER2阴性患者中具有很高的活性并且耐受性良好。 VICTOR-2研究旨在确认这些结果。

著录项

来源
《Breast cancer research and treatment.》 |2016年第3期|共9页
作者
Cazzaniga M. E.; Cortesi L.; Ferzi A.; Scaltriti L.; Cicchiello F.; Ciccarese M.; Della Torre S.; Villa F.; Giordano M.; Verusio C.; Nicolini M.; Gambaro A. R.; Zanlorenzi L.; Biraghi E.; Legramandi L.; Rulli E.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Metronomic chemotherapy; Vinorelbine; Capecitabine; Breast cancer;

机译：节律化疗;维诺瑞滨;卡培他滨;乳腺癌;

相似文献

外文文献
中文文献
专利

1. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study [J] . Cazzaniga M. E., Cortesi L., Ferzi A., Breast cancer research and treatment. . 2016,第3期

机译：在晚期HER2阴性乳腺癌患者中，口服长春瑞滨（mVNR）和卡培他滨（mCAPE）进行节律化疗：这是优化疾病控制的一种方法吗？ VICTOR-2研究的最终结果
2. METRONOMIC CHEMOTHERAPY (CHT) COMBINATION OF VINORELBINE (VRL) AND CAPECITABINE (CAPE) IN HER2-ADVANCED BREAST CANCER (ABC) PATIENTS (PTS) DOES NOT IMPAIR GLOBAL QOL. FIRST RESULTS OF THE VICTOR-2 STUDY [J] . Cazzaniga Marina Elena, Torri Valter, Cortesi Laura, The Breast : . 2015,第Suppla3期

机译：HER2晚期乳腺癌（ABC）患者（PTS）中长春瑞滨（VRL）和卡培他滨（CAPE）的均等化学疗法（CHT）并不会损害全球QOL。 VICTOR-2研究的第一结果
3. METRONOMIC CHEMOTHERAPY (CHT) COMBINATION OF VINORELBINE (VRL) AND CAPECITABINE (CAPE) IN HER2-ADVANCED BREAST CANCER (ABC) PATIENTS (PTS) DOES NOT IMPAIR GLOBAL QOL. FIRST RESULTS OF THE VICTOR-2 STUDY [J] . Cazzaniga Marina Elena, Torri Valter, Cortesi Laura, The Breast : . 2015,第Suppla3期

机译：MER2-先进的乳腺癌（ABC）患者（PTS）在HER2-先进的乳腺癌（ABC）患者（PTS）中的血肠（VRL）和CAPECITABINE（CAPE）组合并不损害全球QOL。 Victor-2研究的第一个结果
4. Use of Laser Photomodulation in the Evolution of Oral Mucositis Associated to Cyclophosphamide, Methotrexate, 5-Fluouracil - CMF in 5 Fluouracil + Adriamycin + Cyclophosphamide - FAC Chemotherapy Protocols in Patients with Breast Cancer [C] . Maria de Fatima Lima Ferreira, Fabiola Bastos de Carvalho, Susana C. P. S. de Oliveira, Mechanisms for low-light therapy VIII . 2013

机译：激光光调节在5种氟尿嘧啶+阿霉素+环磷酰胺-FAC化疗方案中与环磷酰胺，甲氨蝶呤，5-氟尿嘧啶-CMF相关的口腔黏膜演变中的应用
5. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
6. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study [O] . M. E. Cazzaniga, L. Cortesi, A. Ferzi, -1

机译：在晚期HER2阴性乳腺癌患者中口服长春瑞滨（mVNR）和卡培他滨（mCAPE）进行节律化疗：这是优化疾病控制的一种方法吗？ VICTOR-2研究的最终结果
7. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study [O] . M. E. Cazzaniga, null null, L. Cortesi, 2016

机译：在晚期HER2阴性乳腺癌患者中，口服长春瑞滨（mVNR）和卡培他滨（mCAPE）进行节律化疗：这是优化疾病控制的一种方法吗？ VICTOR-2研究的最终结果

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅